What side effects are associated with this type of intervention?

Common treatments for Non-Small Cell Lung Cancer (NSCLC) include chemotherapy agents like docetaxel, immunotherapy agents such as nivolumab and atezolizumab, and targeted therapies like pembrolizumab. Known side effects of these treatments can vary but often include nausea, vomiting, fatigue, skin rash, diarrhea, and immune-related adverse effects such as inflammation of organs (e.g., pneumonitis, colitis). These side effects can impact the patient's quality of life and are important considerations in shared decision-making processes.

What prior FDA approvals exist?

FDA approvals for the treatment of Non-Small Cell Lung Cancer (NSCLC) have included several immunotherapies and targeted therapies that align with the shared decision-making approach. Notable approvals include pembrolizumab (Keytruda) for patients with PD-L1 expressing tumors, nivolumab (Opdivo), and atezolizumab (Tecentriq) for their roles in checkpoint inhibition. Additionally, targeted therapies like osimertinib (Tagrisso) for EGFR mutations and alectinib (Alecensa) for ALK-positive NSCLC have been significant. These treatments offer various options that can be discussed between patients and clinicians to tailor therapy based on individual patient profiles and preferences.

What other types of research exist?

Promising novel alternatives to Decision Aid for NSCLC patients considering treatment in 2024 include: 1) New combination therapies that integrate immunotherapy with targeted treatments, enhancing efficacy and potentially improving patient outcomes. 2) Personalized medicine approaches that use genetic and molecular profiling to tailor treatments to individual patient profiles, increasing the precision and effectiveness of therapy. 3) Enhanced patient education tools that leverage digital platforms to provide comprehensive, accessible information, thereby supporting informed decision-making and patient engagement.

← Back to Search

Decision Aid for Lung Cancer

N/A

Waitlist Available

Led By Donald Sullivan

Research Sponsored by OHSU Knight Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Completed treatment for suspected or confirmed stage I-IV non-small cell lung cancer (NSCLC)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from enrollment to the end of follow-up at 8 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a tool that helps lung cancer patients understand their treatment options and make decisions with their doctors. It aims to improve patient knowledge, reduce uncertainty, and enhance communication. The study evaluates the tool's effectiveness.

Who is the study for?

This trial is for English-speaking individuals with a life expectancy over 6 months who have completed treatment or are undergoing diagnostic work-up for suspected or confirmed stage I-IV non-small cell lung cancer. They must also be cognitively able to participate, as indicated by a score above 3 on a specific cognitive screener.

What is being tested?

The study tests the effectiveness of a decision aid designed to improve decision-making in patients with non-small cell lung cancer. It aims to see if this tool helps patients understand their condition better and make more informed choices about their care alongside their doctors.

What are the potential side effects?

Since the interventions include best practices, informational intervention, and questionnaire administration rather than medical treatments, there are no direct physical side effects expected from participating in this trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have completed treatment for early or advanced non-small cell lung cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and at enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Acceptability of the conversation tool

Feasibility of the conversation tool

Secondary study objectives

Anxiety

Decision making involvement

Decisional Regret

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm I (conversation tool)Experimental Treatment2 Interventions

Patients receive the conversation tool.

Group II: Arm II (usual care)Active Control2 Interventions

Patients receive usual care.

0 / 1Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for Non-Small Cell Lung Cancer (NSCLC) include chemotherapy, immunotherapy, and targeted therapies. Chemotherapy works by killing rapidly dividing cancer cells, but it can also affect normal cells, leading to side effects. Immunotherapy, such as anti-PD-1 or anti-PD-L1 therapies, boosts the body's immune system to recognize and attack cancer cells. Targeted therapies focus on specific genetic mutations within cancer cells, such as EGFR or ALK mutations, to block the growth and spread of cancer. Understanding these mechanisms is crucial for NSCLC patients as it helps them weigh the benefits and risks of each treatment option, align treatments with their personal values and preferences, and actively participate in shared decision-making with their healthcare providers.

The management of non-small-cell lung cancer: a case history.